Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia

Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now.

STATEMENT OF NEED

Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may compromise the efficacy of chemotherapy (Gargiulo et al, 2021). Additionally, among patients with cancer, hospitalizations related to complications of CIN result in substantial medical costs, in addition to increased morbidity and mortality (Li et al, 2020). Therefore, it is essential that members of the multidisciplinary team have a comprehensive understanding of the risk factors, current clinical practice guidelines, emerging data, and management strategies for CIN. In this activity, Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP, will update clinicians on recent developments in the prevention, treatment, and management of CIN.

TARGET AUDIENCE

Oncologists, nurse practitioners, physician associates, oncology nurses, and other health care professionals involved in the treatment of patients with chemotherapy-induced neutropenia (CIN).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

Distinguish patient, tumor, and cancer therapy risk factors for CIN
Evaluate clinical practice guidelines on the management of febrile neutropenia
Assess recent clinical trial findings on novel and emerging agents for CIN prophylaxis and treatment
Apply strategies to prevent and manage infectious complications in patients with CIN